Isoantigens (Alloantigen)

Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.

Also Known As:

Networked: 1094 relevant articles (31 outcomes, 93 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Santoso, Sentot: 9 articles (08/2011 - 02/2002)
2.	Ferrara, James L M: 7 articles (11/2014 - 05/2002)
3.	Reddy, Pavan: 7 articles (01/2014 - 06/2002)
4.	Liu, Chen: 6 articles (09/2015 - 06/2002)
5.	Robinson, James: 6 articles (01/2014 - 01/2005)
6.	Marsh, Steven G E: 6 articles (01/2014 - 01/2005)
7.	Kroll, Hartmut: 6 articles (08/2011 - 03/2005)
8.	Aster, Richard H: 5 articles (06/2015 - 08/2004)
9.	Curtis, Brian R: 5 articles (06/2015 - 08/2004)
10.	Blazar, Bruce R: 4 articles (02/2015 - 06/2003)

Related Diseases

1.	Neoplasms (Cancer) 11/01/1996 - "Removal of the Mac-1-positive cells from the tumor-bearing hosts spleen relieved suppression of the tumor-bearing mouse spleen cell proliferative response to alloantigens, and addition of the Mac-1-positive enriched cells suppressed proliferation of normal T cells in response to alloantigens. " 01/01/1983 - "A recurrence of blood group isoantigens was demonstrated in patients who achieved tumor remission. " 02/01/1981 - "In addition, A, B and H antigenicity was assessed and showed a recurrence of initially lacking surface isoantigens in patients with tumor remission." 05/01/1999 - "These studies illustrate that costimulation is necessary for tumor cells to function as alloantigen-presenting cells. " 03/01/1995 - "To demonstrate a cellular basis for immune resistance to the YC8 tumor, BALB/c mice primed with DBA/2 spleen cell alloantigen were conditioned using a single trial CS/US association paradigm. "
2.	Lymphopenia (Lymphocytopenia) 06/15/2000 - "Together, these observations suggest that activation of T cells in vivo, presumably by alloantigens, predisposes the cells to spontaneous apoptosis, and this phenomenon is associated with lymphopenia. " 10/01/1989 - "The gene for the T lymphocyte alloantigen, RT6, is not linked to either diabetes or lymphopenia and is not defective in the BB rat." 11/01/1986 - "Immunologic abnormalities included absolute T-cell lymphopenia and markedly reduced in vitro lymphocyte responses to phytohemagglutinin and to alloantigen in the mixed lymphocyte reaction. " 11/01/1991 - "A number of T-cell abnormalities including lymphopenia, poor cell-mediated responsiveness to alloantigen, and an absence of an RT6+ T-cell subset are associated with disease susceptibility. " 12/01/1998 - "Anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third party alloantigen is seen in acute lethal GVH disease. "
3.	Anemia 12/01/1992 - "This disorder is characterized by anemia, a diminished number of splenocytes, impaired cytotoxicity (CTX) against third party alloantigen, and impaired natural killer cell (NK) activity. " 12/01/1998 - "Anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third party alloantigen is seen in acute lethal GVH disease. " 08/01/1995 - "Acute lethal GVH disease is characterized by anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third-party alloantigen. " 10/01/1993 - "Acute lethal GVH disease is characterized by anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third-party alloantigen. "
4.	Agammaglobulinemia (Hypogammaglobulinemia) 12/01/1998 - "Anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third party alloantigen is seen in acute lethal GVH disease. " 08/01/1995 - "Acute lethal GVH disease is characterized by anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third-party alloantigen. " 10/01/1993 - "Acute lethal GVH disease is characterized by anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third-party alloantigen. "
5.	Graft vs Host Disease (Graft-Versus-Host Disease) 08/01/1996 - "Results of a previous study showed that donor T cells were most effective for preventing rejection when they recognize an alloantigen expressed by recipient T cells and can cause graft-versus-host disease (GVHD). " 03/15/2012 - "Importantly, alloantigen-primed and CD4(+) T cell-helped macrophages (licensed macrophages) exhibit potent regulatory function in vivo in an acute graft-versus-host disease model. " 05/01/2002 - "In this study, we investigated the possibility of selective depletion of donor alloantigen-specific T cells from C57BL/6 (H-2(b)) mice to prevent graft-versus-host disease (GVHD). " 05/01/1992 - "The pretransplant alloantigen-dependent responding and stimulating capacity of donors and of recipients was studied retrospectively, in a study of prediction of acute graft-versus-host disease. " 04/01/1987 - "Study of a human minor alloantigen in relation to clinical graft-versus-host disease."

Related Drugs and Biologics

1.	Antigens
2.	HLA-B7 Antigen (HLA B7 Antigen)
3.	Cyclophosphamide (Cytoxan)
4.	Interleukin-2 (IL2)
5.	Monoclonal Antibodies
6.	Histocompatibility Antigens Class II
7.	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
8.	Immunoglobulin G (IgG)
9.	A-Form DNA (A-DNA)
10.	Cancer Vaccines

Related Therapies and Procedures

1.	Homologous Transplantation (Allograft)
2.	Transplants (Transplant)
3.	Hematopoietic Stem Cell Transplantation
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
5.	Platelet Transfusion (Blood Platelet Transfusions)